Glaxosmithkline Share News (GSK)

UPDATE 3-Drugmakers to join forces to make millions of Ebola vaccine doses

* J&J says has discussed collaboration with GlaxoSmithKline * J&J investing up to $200 mln to accelerate programme * Bavarian Nordic to receive cash injection from J&J (Recasts, adds comment on collaboration) By Ben Hirschler LONDON, Oct 22 (Reuters) - Leading drugmakers

GlaxoSmithKline holds dividend, eyes IPO of HIV unit

LONDON, Oct 22 (Reuters) - GlaxoSmithKline kept its dividend unchanged for the third quarter, breaking a run of steadily rising payouts, as U.S. pricing pressure on its top-selling lung drug Advair eroded sales and profit. Britain's biggest drugmaker said on Wednesday its 2015 dividend was

BUZZ-Glaxo tops FTSE on Q3 earnings beat

** GlaxoSmithKline rises 4.6 pct after reporting Q3 EPS of 27.9p, up 5 pct and above the 24p forecast by analysts. ** Biggest one-day rise for stock since April. ** Top riser on FTSE 100 at 1100 GMT. ** Q3 dividend maintained at 19p/shr FY 2014 div expected to be 80p, up 3 pct,

CORRECT: MARKET COMMENT: Earnings Drive Mixed UK Stocks

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON, Oct 22 (Reuters) - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration. J&J, which aims to have at least 1 million doses of its

Wednesday broker round-up UPDATE

Amino Technologies: N+1 Singer moves target price from 93p to 107p upgrading to buy. Anglo American: Liberum Capital reduces target price from 1300p to 1200p retaining its sell recommendation. ARM Holdings: UBS moves target price from 970p to 980p upgrading from neutral to buy. Deutsche Bank cuts t

MARKET COMMENT: Earnings Drive Mixed UK Stocks, As BOE Stands Pat

UPDATE 2-J&J aims for 1 million Ebola vaccine doses in 2015

* Companies racing to develop first approved Ebola vaccine * J&J investing up to $200 mln to accelerate programme * Bavarian Nordic to receive cash injection from J&J * GSK and NewLink currently leading in vaccine development (Adds Bavarian Nordic share price jump, further det

UPDATE 1-J&J aims for 1 million Ebola vaccine doses in 2015

* Companies racing to develop first approved Ebola vaccine * J&J investing up to $200 mln to accelerate programme * Bavarian Nordic to receive cash injection from J&J * GSK and NewLink currently leading in vaccine development (Adds details on other vaccines, context) By

MARKET COMMENT: UK Stocks To Open Higher Ahead Of BoE Minutes

UK Earnings, Trading Statements Calendar - Week Ahead

REFILE-MSF aims to start drug trials in Ebola clinics next month

(Refiles to fix typo in first paragraph.) * MSF says priority will be treatments already available * Hopes trials can begin in November * MSF would not approve use of placebo in drug trials * Women and children should be included in tests By Daniel Flynn DAKAR,

MSF aims to start drug trials in Ebola clinics next month

* MSF says priority will be treatments already available * Hopes trials can begin in November * MSF would not approve use of placebo in drug trials * Women and children should be included in tests By Daniel Flynn DAKAR, Oct 21 (Reuters) - The medical charity Medecine

MARKET COMMENT: UK Stocks Gain As ECB Stimulus Hopes Boost Equities

RPT-Tens of thousands expected to get Ebola vaccines from January - WHO

(Repeats to additional clients.) * Clinical trials now under way to yield data on dosage * Health workers should get GSK, NewLink vaccines in Jan * Johnson & Johnson, Russia also have candidate vaccines By Stephanie Nebehay GENEVA, Oct 21 (Reuters) - Tens of thousand